Switching From Compounded to Branded: How Big the Step Really Is

People switch from a compounded GLP-1 to an FDA-approved one for all sorts of reasons, and almost everyone budgets for it by subtracting one monthly price from another. That is the wrong arithmetic, and it is wrong in a consistent direction: it understates the step.

Four things change at the same time. Only one of them is the drug price.

One: a flat price becomes a ladder, and you enter it at your dose

Compounded sellers overwhelmingly charge a single price whatever strength you are on. Found's pricing FAQ puts it plainly: "Compounded medications are included in the cost of both insurance and cash-pay plans."¹ Zealthy sells a flat "Semaglutide Bundle: $217 for your first month, then $297 per month".²

Branded pricing is not flat. LillyDirect charges $299 a month for Zepbound® at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above.³ Novo charges $349 for most Wegovy® pen doses and $399 for the 7.2 mg high-dose pen.⁴

Here is the part people miss. If you have been on a compounded product for a year, you are not starting a branded course at the bottom of the ladder. You arrive at whatever tier your current strength maps to. The $299 entry price on the tirzepatide ladder is a starting-dose price, and a switcher generally never sees it.

Two: the introductory offer is probably not available to you

Novo's $199 pen price looks like the obvious landing spot for a switcher. Read the footnote: "Patients new to Wegovy® Savings Offer & NovoCare® Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg. Offer for 2 monthly fills through December 31, 2026."⁴

Two conditions, and most switchers fail at least one. It applies only to the 0.25 and 0.5 mg doses — the two lowest — so anyone arriving at a higher strength pays $349 from the first fill regardless. And it applies only to patients new to the offer and to NovoCare Pharmacy.

The Ozempic® pen offer carries the same two restrictions.⁵

Three: the membership may not go away

This is where the sentence from Found's own FAQ earns its place. The full quote: "Compounded medications are included in the cost of both insurance and cash-pay plans. Branded GLP-1 medication may also be available but their cost is billed separately and isn't included in the prices listed above."¹

Read that as a bill. Before the switch, $289 a month buys care and medication. After the switch, $289 a month buys care, and the medication is a second charge on top. The plan price does not fall to make room for it.

The same shape shows up at telehealth companies that resell branded product directly. Ro charges $39 to start and then $149 a month for the care layer, on top of a medication line that runs $299, $399 or $449 for Zepbound — $598 a month all-in at the top tier.⁶ Our Ro review and Found review take both bills apart.

Four: the length of a month changes

Compounded and branded products are not billed on the same clock, and the mismatch shows up as an extra fill you did not plan for.

LillyDirect defines a Zepbound month as 28 days, so 365 days holds about 13 fills.³ A Novo pen month is one box of four weekly pens — also 28 days. A Novo tablet month is one bottle of 30 tablets, so about 12.2 fills. Found bills monthly plans at $289.¹

Multiply the wrong number by twelve and a Zepbound year comes out $449 light.

The cheapest version of this switch, and the dearest

Two switchers, same starting point — a compounded plan at roughly $289 a month, or about $3,468 over twelve cycles.

Cheapest: switch to the branded Wegovy tablet and settle at its maintenance tier of $299 a month over twelve 30-day fills. That is $3,588 a year. The step is $120 for the year — about ten dollars a month for a product with an FDA approval behind it.

Dearest: switch to branded Zepbound resold through a telehealth membership at $598 a month all-in. Over a year that is $6,916. The step is $3,448.

Both switches move a reader from a compounded product to an FDA-approved one. One costs ten dollars a month. The other costs nearly three hundred. The variable is not the molecule; it is the form and the channel.

Which is why the channel is worth picking deliberately. We price every route to an approved GLP-1 the same way, from the manufacturer's own pharmacy to the telehealth resellers, on the branded GLP-1 board.

What does not change

The clinical reason you are switching, which is not ours to comment on. And your plan's cost sharing, which no plan publishes per drug — so nothing above is an insured price.

It is also worth noting what you gain, in the FDA's own framing rather than ours: compounded drugs "are not FDA-approved", the agency "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed", and a compounded drug is not the same regulatory object as a generic, which must establish therapeutic equivalence.⁷ Whatever the step costs, that is what it buys.

What we could not price

We could not price Found's branded GLP-1 route, because Found states that branded medication is billed separately and does not publish the figure. The $289 above is therefore a floor for that switch, not a total.

No compounded seller we read describes a transition credit or a prorated final cycle.

And we could not price the Wegovy 7.2 mg high-dose pen against a compounded equivalent, because no compounded seller we priced publishes a strength-matched product.

Related: compounded semaglutide vs branded Wegovy, compounded tirzepatide vs branded Zepbound, and the live spread on the compounded semaglutide board.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S; Zepbound® is a registered trademark of Eli Lilly and Company.